AVEO Pharmaceuticals, Inc.

Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia

Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia

February 16, 2011

TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Astellas Pharma Inc. (TSE: 4503, “Astellas”), a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO, “AVEO”) today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

BG Medicine, Inc.

BG Medicine Announces Exercise of Underwriters' Over-Allotment Option and Closing of Initial Public Offering

BG Medicine Announces Exercise of Underwriters' Over-Allotment Option and Closing of Initial Public Offering

February 9, 2011

WALTHAM, Mass.--(BUSINESS WIRE)-- BG Medicine (NASDAQ: BGMD) today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of BG Medicine's common stock at $7.00 per share, less underwriting discounts and commissions.

Novomer, Inc.

Novomer Wins InformexUSA Sustainability Award

Novomer Wins InformexUSA Sustainability Award

February 9, 2011

BOSTON, MA--(Marketwire - February 9, 2011) - Novomer Inc., a sustainable materials company pioneering a family of high-performance plastics, polymers and other chemicals from renewable feedstocks such as carbon dioxide (CO2), today announced that it has been recognized with a InformexUSA 2011 Profiles in Sustainability Award. Novomer was honored during the show's awards gala held last night at the Charlotte Convention Center.

Affinnova, Inc.

Affinnova Triples the Likelihood of Beating Leading Competitors

Affinnova Triples the Likelihood of Beating Leading Competitors

February 9, 2011

Waltham, MA, February 09, 2011 – Affinnova, the global leader in marketing innovation software and services, today announced that 64% of client initiatives using their IDDEA software produce optimized concepts that outscore their leading competitor. Conversely, pre-optimization concepts from the same initiatives beat their leading competitor only 22% of the time. These findings are the result of a yearlong study of all client initiatives using Affinnova’s IDDEA II software with competitive benchmark measurement capabilities.

LS9

LS9 Announces Second Partnership with Procter & Gamble

LS9 Announces Second Partnership with Procter & Gamble

February 7, 2011

SOUTH SAN FRANCISCO, CA - February 7, 2011 - LS9, Inc. today announced the initiation of a second development and commercialization partnership with Procter & Gamble (NYSE: PG). This additional partnership draws on LS9's unique technology to broaden the portfolio of renewable chemicals to be used in P&G's consumer products.

Accuri Cytometers, Inc.

BD Announces Agreement to Acquire Accuri Cytometers, Inc.

BD Announces Agreement to Acquire Accuri Cytometers, Inc.

February 7, 2011

 

BG Medicine, Inc.

BG Medicine Announces Pricing of Initial Public Offering

BG Medicine Announces Pricing of Initial Public Offering

February 4, 2011

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine (NASDAQ: BGMD) today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price of $7.00 per share, before underwriting discounts and commissions. All shares are being sold by the Company.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib

AVEO Pharmaceuticals Initiates Enrollment in a Phase 2 Exploratory Biomarker Study of Tivozanib

February 1, 2011

CAMBRIDGE, Mass., Feb 01, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with renal cell carcinoma (RCC).

Joule Unlimited, Inc.

Joule Biotechnologies Names Bill Sims President and CEO

Joule Biotechnologies Names Bill Sims President and CEO

July 27, 2009

Cambridge, Mass.—July 27, 2009—Joule Biotechnologies, Inc., an innovative bioengineering startup developing game-changing alternative energy solutions, today announced the appointment of Bill Sims as president and CEO. Sims brings nearly 30 years of experience growing both emerging and established companies across multiple technology and product sectors. In addition to his new position, he will continue to serve on the company’s board of directors.

Mascoma Corporation

Mascoma Announces Feedstock Processing and Lignin Supply Agreement with Chevron Technology Ventures

Mascoma Announces Feedstock Processing and Lignin Supply Agreement with Chevron Technology Ventures

September 14, 2009

 Lebanon, New Hampshire – September 14, 2009 – Mascoma Corporation today announced that it has entered into a feedstock processing and lignin supply agreement with Chevron Technology Ventures (CTV), a division of Chevron U.S.A., Inc.

Under terms of the agreement, CTV will provide various sources of lignocellulosic feedstock to Mascoma. Mascoma will then convert the feedstock to cellulosic ethanol through its proprietary process, which produces lignin as a by-product. Mascoma will provide this lignin to CTV for evaluation.